Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GH Secretagogue

CJC-1295 vs Hexarelin

CJC-1295 and Hexarelin target different GH-release pathways and occupy opposite ends of the secretagogue potency-versus-cleanliness trade-off. CJC-1295 maintains sustained GHRH tone. Hexarelin drives the strongest acute GH pulse in the secretagogue class but with off-target endocrine effects.

Bangkok research desk ·

Side-by-side

CJC-1295 Hexarelin
MechanismModified GHRH(1-29) with DAC; extended half-life.Potent hexapeptide ghrelin-receptor agonist.
Half-life~8 days.Short.
Dose1-2 mg weekly SC.100 mcg × 2-3 daily SC.
Cycle12 weeks on / 4 off.4-8 weeks; receptor desensitisation limits longer cycles.
Research contextSustained GH/IGF-1 elevation in volunteer studies1.Strong acute GH release; higher cortisol and prolactin impact than selective GHS2.
Cost tierMid.Low-to-mid.

CJC-1295 and Hexarelin approach GH stimulation from opposite directions. CJC-1295 operates at the GHRH receptor with sustained tone; Hexarelin is a potent ghrelin-receptor agonist with short half-life and strong acute GH release2. Research protocols that need sustained IGF-1 elevation lean toward CJC-1295. Protocols that target acute GH pulse magnitude lean toward Hexarelin, with the caveat that Hexarelin has more off-target endocrine activity than cleaner GHS compounds.

Hexarelin's trade-off is the reason it is used in shorter cycles. The compound produces the strongest acute GH release among commonly studied ghrelin-receptor agonists, but cortisol and prolactin elevation are more pronounced than with selective GHS such as Ipamorelin. Research protocols typically run 4-8 weeks to limit receptor desensitisation and the endocrine side profile. CJC-1295's 12-week cycle reflects its different pharmacological target and sustained-tone mechanism.

Stacking the two is plausible on paper because they target different receptors, but the research literature tends to pair CJC-1295 with cleaner GHS compounds (Ipamorelin is the standard partner) rather than with Hexarelin, because the goal of the stack is typically pulsatility plus sustained tone without the endocrine noise. Hexarelin shows up more often as a standalone acute-potency tool or in elderly-subject studies examining GH-releasing capacity2. See the GH secretagogue cycle design for cycle planning across the class.

Frequently asked

Why not always pair CJC-1295 with Hexarelin?
Hexarelin raises cortisol and prolactin more than selective GHS such as Ipamorelin. For sustained research protocols where endocrine cleanliness matters, Ipamorelin is the more common pairing. Hexarelin is used where acute GH pulse magnitude is the primary endpoint.
Is Hexarelin shorter-cycled for a specific reason?
Yes. Its potency drives faster receptor desensitisation and the elevated cortisol/prolactin profile compounds over time. 4-8 week cycles are the conservative choice in the literature.
Which has stronger human data?
CJC-1295 has the cleaner human volunteer data in terms of sustained IGF-1 elevation1. Hexarelin has older human data focused on acute GH release and receptor pharmacology2, including in elderly-subject populations.
Research desk
Ordering both CJC-1295 and Hexarelin for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID: 16352683
  2. Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide. J Clin Endocrinol Metab. 1994. PMID: 8126144

All references verified against PubMed via NCBI E-utilities.